GlassScriptPhysician profile
Rachel Mcadams
NPI 1528244472
$3,719.46
in general payments reported to CMS, 2019-2025
31 companies · $447 in 2025
The $447 reported for 2025 was more than what 79% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $973 · 2022: $1,075 · 2023: $730 · 2024: $494 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.47 |
| Education | $116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $694.32 | 2021-2025 | Veozah |
| Abbvie INC. | $506.69 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $364.13 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $292.16 | 2021-2022 | |
| Daiichi Sankyo INC. | $244.74 | 2021-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $216.53 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $180.57 | 2021-2025 | |
| Organon LLC | $168.64 | 2021-2024 | Nexplanon |
| Biogen, INC. | $158.52 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $154.31 | 2021-2025 | Slynd |
| Axonics, INC. | $115.35 | 2021-2022 | |
| Evofem Biosciences, INC. | $101.11 | 2021-2023 | Phexxi |
| Therapeuticsmd, INC. | $69.89 | 2021-2022 | |
| Scynexis, INC. | $63.59 | 2022 | |
| Agile Therapeutics, INC. | $46.82 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.50 | 2023 | Evenity, Prolia |
| Boston Scientific Corporation | $32.45 | 2023 | Upsylon |
| Urovant Sciences INC | $30.12 | 2021-2022 | |
| Millicent US INC | $26.70 | 2024 | |
| Amag Pharmaceuticals, INC. | $24.40 | 2021 | |
| Lilly USA, LLC | $22.16 | 2025 | Zepbound |
| Pfizer INC. | $21.77 | 2023 | |
| Abbott Laboratories | $20.65 | 2023 | Proclaim |
| Merck Sharp & Dohme LLC | $17.82 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $16.15 | 2022 | |
| Coopersurgical, INC. | $16.10 | 2025 | Paragard T 380a |
| Hologic Sales and Service, LLC | $15.23 | 2023 | Aptima |
| Teleflex LLC | $15.16 | 2021 | |
| Novo Nordisk INC | $14.90 | 2022 | |
| Coloplast Corp | $13.34 | 2021 | |
| Aspira Women'S Health INC | $11.64 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.